Among disruptive variants in EFCAB13, the stop-gain SNV rs118004742 showed the most consistent pattern of statistically significant association among the three cohorts and combining the entire cohort of 2390 MS patients and 2342 HC in the meta-analysis. This evidence concerns the gene EFCAB13 and myeloid sarcoma.